Abiraterone acetate and prednisolone for metastatic castration‐resistant prostate cancer failing androgen deprivation and docetaxel‐based chemotherapy: A phase <scp>II</scp> bridging study in <scp>K</scp>orean and <scp>T</scp>aiwanese patients

Abstract

A combination of abiraterone acetate and prednisolone appears to be a favorable second-line treatment in Taiwanese and Korean patients with advanced metastatic castration-resistant prostate cancer after failed docetaxel-based chemotherapy.